Clinical Trial

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Primary Objective To evaluate the preliminary efficacy of Purinostat Mesylate for Injection in patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Secondary Objectives 1. To evaluate the safety and tolerability of Purinostat Mesylate for Injection in patients with relapsed or refractory PTCL and CTCL. 2. To evaluate the population pharmacokinetic characteristics of Purinostat Mesylate for Injection in patients with relapsed or refractory PTCL and CTCL. Exploratory Objective To investigate the relationship between tumor biomarkers and the therapeutic efficacy/safety profile of Purinostat Mesylate for Injection.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-26; most recent amendment 2026-02-03.
Status change: Recruiting → Active, Not Recruiting 2026-02-03
Trial Details
NCT Number NCT06485219
Lead Sponsor Chengdu Zenitar Biomedical Technology Co., Ltd
Conditions Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
Enrollment 50 participants
Start Date 2024-04-14
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-06